To Congress, From Pharma: Love, Hate And Fresh Ideas For 21st Century Cures
Industry and key stakeholders weigh in on House Commerce Committee’s first take at biomedical reform; brand companies offer lots of positive feedback but want many modifications; generic companies criticize multitude of new exclusivity provisions for brands.
You may also be interested in...
Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.
Providing a transferable period of patent-life extension in exchange for US FDA approval of a new antibiotic would incentivize ‘the whole ecosystem’ to find new treatments for emerging diseases, CEO Ian Read says.
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.